Management of regorafenib-related toxicities: a review

Regorafenib (Stivarga, BAY 73-4506; Bayer Pharma AG, Berlin, Germany) is an oral multikinase inhibitor that targets the angiogenic tumor microenvironment and oncogenic kinases including vascular endothelial growth factor receptor 2 (VEGFR2), VEGFR1, VEGFR3, fibroblast growth factor receptor 1 (FGFR1...

Full description

Saved in:
Bibliographic Details
Published in:Therap Adv Gastroenterol
Main Authors: Krishnamoorthy, Saravanan K., Relias, Valerie, Sebastian, Sunit, Jayaraman, Vijay, Saif, Muhammad Wasif
Format: Artigo
Language:Inglês
Published: SAGE Publications 2015
Subjects:
Reviews
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4530428/
https://ncbi.nlm.nih.gov/pubmed/26327919
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X15580743
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items